Rhapsido (remibrutinib) represents a significant advancement in chronic spontaneous urticaria (CSU) management following Rhapsido FDA approval on September 30, 2025. This first-in-class oral Bruton’s tyrosine kinase (BTK) inhibitor addresses a critical clinical gap for the estimated 1-2 million CSU patients failing…
Acromegaly, a rare endocrine disorder caused by excess growth hormone (GH), has posed immense challenges in clinical management. For decades, patients with inadequate surgical response or inoperable cases relied on complex regimens of injectable somatostatin analogs. PALSONIFY (paltusotine), newly approved…
In pharmaceutical manufacturing, aseptic processing control is the distinct methodology used to produce sterile drug products that cannot be terminally sterilized due to thermal instability. Unlike terminal sterilization, which destroys microorganisms in the final sealed container, aseptic processing relies on…
As the pharmaceutical landscape becomes increasingly complex, the US Food and Drug Administration (USFDA) has definitively shifted from a purely reactive, punitive compliance model to a proactive, risk-based oversight framework. This strategic evolution, championed by the principles of ICH Q9…
As the pharmaceutical landscape evolves, so too does the rigor of the U.S. Food and Drug Administration’s (FDA) oversight. The Pre-Approval Inspection (PAI) e.g. USFDA PAI checklist remains the critical gatekeeper, serving two primary objectives: to verify the authenticity and…
The landscape of endocrine therapy for hormone receptor-positive (HR+) breast cancer continues to evolve rapidly, particularly for patients whose disease has become resistant to standard-of-care treatments. On September 25, 2025, the FDA approved INLURIYO (imlunestrant) tablets, a new oral selective…
In the rapidly evolving landscape of regulated industries, 21 CFR Part 11 compliance remains a cornerstone of digital transformation and regulatory adherence. This USFDA regulation establishes the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and…
A USFDA Warning Letter (WL) is more than a mere correspondence; it is a public declaration of significant non-compliance with the Federal Food, Drug, and Cosmetic Act, posing an immediate, existential threat to a pharmaceutical, medical device, or biologics operation.…
For global pharmaceutical and medical device manufacturers, particularly those operating in high-volume markets like the US and India, the receipt of an FDA Form 483, Inspectional Observations, is not merely a documentation step—it is a critical inflection point. In the…
For pharmaceutical manufacturers, especially those eyeing the lucrative United States market, USFDA pharma compliance and Inspection readiness is not merely a regulatory hurdle; it is the cornerstone of commercial viability and corporate reputation. The U.S. Food and Drug Administration (FDA)…